Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux

Rituximab is a second‐line option in adults with immune thrombocytopenia (ITP), but the estimated 5‐year response rate, only based on pooled retrospective data, is about 20%, and no studies have focused on long‐term safety. We conducted a prospective multicenter registry of 248 adults with ITP treat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hematology 2019-12, Vol.94 (12), p.1314-1324
Hauptverfasser: Deshayes, Samuel, Khellaf, Mehdi, Zarour, Anissa, Layese, Richard, Fain, Olivier, Terriou, Louis, Viallard, Jean‐François, Cheze, Stéphane, Graveleau, Julie, Slama, Borhane, Audia, Sylvain, Cliquennois, Manuel, Ebbo, Mikael, Le Guenno, Guillaume, Salles, Gilles, Bonmati, Caroline, Teillet, France, Galicier, Lionel, Lambotte, Olivier, Hot, Arnaud, Lefrère, François, Mahévas, Matthieu, Canoui‐Poitrine, Florence, Michel, Marc, Godeau, Bertrand
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!